Redefining Cellular Regeneration from Adipose Tissue
We harness MSC derived exosomes through the Lipogems® platform, an FDA cleared device proven in 50,000+ procedures worldwide, to pioneer consistent, scalable therapeutics for inflammation and regenerative medicine.
An early stage Swiss biotech built around Lipogems®, an FDA cleared device deployed in 50,000+ procedures, producing exosomes that are fundamentally more bioactive than any conventionally isolated alternative.
Exosome Platform
Proprietary isolation methodology producing highly efficacious, consistent exosomes from MSC rich autologous adipose tissue.
FDA-Cleared Technology
Built on Lipogems® FDA cleared since 2014 for autologous adipose tissue processing across orthopaedics and surgical specialties.
Proven, cost-effective biopharmaceutical production know how enabling clinical grade exosome scale without sacrificing efficacy.
Scalable Manufacturing
A new class of regenerative therapeutic
what we do
"To disrupt the field of inflammation and regenerative medicine by enabling consistent production of highly efficacious exosomes based on FDA cleared technology combined with proven, scalable biopharmaceutical manufacturing know how."
Our mission
Let's explore
what's possible
Get In Touch
Whether you are an investor, clinician, scientific collaborator, or potential partner, we want to hear from you.
